Personalized treatment strategies in glioblastoma: MGMT promoter methylation status

References

• LouisDNOhgakiHWiestlerODThe 2007 WHO classification of tumours of the central nervous systemActa Neuropathol200711429710917618441
   PubMed Web of Science ®Google Scholar
• CrocettiETramaAStillerCEpidemiology of glial and non-glial brain tumours in EuropeEur J Cancer201248101532154222227039
   PubMed Web of Science ®Google Scholar
• SampsonJHMitchellDAIs cytomegalovirus a therapeutic target in glioblastoma?Clin Cancer Res201117144619462121632859
   PubMed Web of Science ®Google Scholar
• PreusserMde RibaupierreSWöhrerACurrent concepts and management of glioblastomaAnn Neurol201170192121786296
   PubMed Web of Science ®Google Scholar
• SchererHJA critical review: the pathology of cerebral gliomasJ Neurol Psychiatry19403214717721610973
   PubMedGoogle Scholar
• NobusawaSWatanabeTKleihuesPOhgakiHIDH1 mutations as molecular signature and predictive factor of secondary glioblastomasClin Cancer Res200915196002600719755387
   PubMed Web of Science ®Google Scholar
• WatanabeKTachibanaOSataKYonekawaYKleihuesPOhgakiHOverexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomasBrain Pathol1996632172238864278
   PubMed Web of Science ®Google Scholar
• OhgakiHDessenPJourdeBGenetic pathways to glioblastoma: a population-based studyCancer Res200464196892689915466178
   PubMed Web of Science ®Google Scholar
• BarkerFG2ndChangSMHuhnSLAge and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumorsCancer19978059369419307194
   PubMed Web of Science ®Google Scholar
• KunzMThonNEigenbrodSHot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomasNeuro Oncol201113330731621292686
   PubMed Web of Science ®Google Scholar
• PöpperlGKrethFWMehrkensJHFET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour gradingEur J Nucl Med Mol Imaging200734121933194217763848
   PubMed Web of Science ®Google Scholar
• JansenNLSchwartzCGrauteVPrediction of oligodendroglial histology and LOH 1p/19q using dynamic [18F]FET-PET imaging in intracranial WHO grade II and III gliomasNeuro Oncol201214121473148023090986
   PubMed Web of Science ®Google Scholar
• PöpperlGGoldbrunnerRGildehausFJO-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastomaEur J Nucl Med Mol Imaging20053291018102515877226
   PubMed Web of Science ®Google Scholar
• JansenNLSuchorskaBSchwarzSB[18F]fluoroethyltyrosine-positron emission tomography-based therapy monitoring after stereotactic iodine-125 brachytherapy in patients with recurrent high-grade gliomaMol Imaging201312313714723490440
   PubMed Web of Science ®Google Scholar
• GotzIGrosuAL[(18)F]FET-PET imaging for treatment and response monitoring of radiation therapy in malignant glioma patients: a reviewFront Oncol2013310423630666
   PubMedGoogle Scholar
• van den BentMJInterobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspectiveActa Neuropathol2010120329730420644945
   PubMed Web of Science ®Google Scholar
• StuppRMasonWPvan den BentMJRadiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J Med20053521098799615758009
   PubMed Web of Science ®Google Scholar
• StuppRHegiMEMasonWPvan den BentMJTaphoornMJJanzerRCEffects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialLancet Oncol200910545946619269895
   PubMed Web of Science ®Google Scholar
• ThomasRPRechtLNagpalSAdvances in the management of glioblastoma: the role of temozolomide and MGMT testingClin Pharmacol201351923293540
   PubMedGoogle Scholar
• ChinotOLde La Motte RougeTMooreNAVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiformeAdv Ther201128433434021432029
   PubMed Web of Science ®Google Scholar
• ChinotOWickWMasonWPhase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma: mature progression-free survival and preliminary overall survival results in AVAglioNeuro Oncol20121410110322013168
   PubMed Web of Science ®Google Scholar
• FiorentinoABalducciMDe BonisPCan elderly patients with newly diagnosed glioblastoma be enrolled in chemoradiotherapy trials?Am J Clin Oncol252013 [Epub ahead of print.]
   Web of Science ®Google Scholar
• ThonNEigenbrodSGrasbon-FrodlEMPredominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomideJ Neurol Neurosurg Psychiatry201182444144620861061
   PubMed Web of Science ®Google Scholar
• WiestlerBClausRHartliebSAMalignant astrocytomas of elderly patients lack favorable molecular markers: an analsis of the NOA-08 study collectiveNeuro Oncol20131581017102623595628
   PubMed Web of Science ®Google Scholar
• WickWPlattenMMeisnerCTemozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trialLancet Oncol201213770771522578793
   PubMed Web of Science ®Google Scholar
• Gállego Pérez-LarrayaJDucrayFChinotOTemozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trialJ Clin Oncol201129223050305521709196
   PubMed Web of Science ®Google Scholar
• GulatiSJakolaASJohannesenTBSolheimOSurvival and treatment patterns of glioblastoma in the elderly: a population-based studyWorld Neurosurg201278551852622381305
   PubMed Web of Science ®Google Scholar
• NiyaziMSchwarzSBSuchorskaBBelkaCRadiotherapy with and without temozolomide in elderly patients with glioblastomaStrahlenther Onkol2012188215415922231634
   PubMed Web of Science ®Google Scholar
• StuppRTonnJCBradaMPentheroudakisGHigh-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201021Suppl 5v190v19320555079
   PubMed Web of Science ®Google Scholar
• TonnJCThonNSchnellOKrethFWPersonalized surgical therapyAnn Oncol201223Suppl 10x28x3222987977
   PubMed Web of Science ®Google Scholar
• StummerWPichlmeierUMeinelTWiestlerODZanellaFReulenHJFluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trialLancet Oncol20067539240116648043
   PubMed Web of Science ®Google Scholar
• StummerWTonnJCMehdornHMCounterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. Clinical articleJ Neurosurg2011114361362320397896
   PubMed Web of Science ®Google Scholar
• LawsERParneyIFHuangWSurvival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes ProjectJ Neurosurg200399346747312959431
   PubMed Web of Science ®Google Scholar
• OszvaldAGüresirESetzerMGlioblastoma therapy in the elderly and the importance of the extent of resection regardless of ageJ Neurosurg2012116235736421942727
   PubMed Web of Science ®Google Scholar
• LacroixMAbi-SaidDFourneyDRA multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survivalJ Neurosurg200195219019811780887
   PubMed Web of Science ®Google Scholar
• SenftCBinkAFranzKVatterHGasserTSeifertVIntraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trialLancet Oncol20111211997100321868284
   PubMed Web of Science ®Google Scholar
• SanaiNPolleyMYMcDermottMWParsaATBergerMSAn extent of resection threshold for newly diagnosed glioblastomasJ Neurosurg201111513821417701
   PubMed Web of Science ®Google Scholar
• GulatiSJakolaASNerlandUSWeberCSolheimOThe risk of getting worse: surgically acquired deficits, perioperative complications, and functional outcomes after primary resection of glioblastomaWorld Neurosurg201176657257922251506
   PubMed Web of Science ®Google Scholar
• BashirRHochbergFOotRRegrowth patterns of glioblastoma multiforme related to planning of interstitial brachytherapy radiation fieldsNeurosurgery198823127302845294
   PubMed Web of Science ®Google Scholar
• JansenEPDewitLGvanHMBartelinkHTarget volumes in radiotherapy for high-grade malignant glioma of the brainRadiother Oncol200056215115610927133
   PubMed Web of Science ®Google Scholar
• WallnerKEGalicichJHKrolGArbitEMalkinMGPatterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytomaInt J Radiat Oncol Biol Phys1989166140514092542195
   PubMed Web of Science ®Google Scholar
• AydinHSillenbergIvonLHPatterns of failure following CT-based 3-D irradiation for malignant gliomaStrahlenther Onkol2001177842443111544905
   PubMed Web of Science ®Google Scholar
• NiyaziMSiefertASchwarzSBTherapeutic options for recurrent malignant gliomaRadiother Oncol201198111421159396
   PubMed Web of Science ®Google Scholar
• MandlESDirvenCMBuisDRPostmaTJVandertopWPRepeated surgery for glioblastoma multiforme: only in combination with other salvage therapySurg Neurol200869550650918262245
   PubMedGoogle Scholar
• GuyotatJSignorelliFFrappazDMadarassyGRicciACBretPIs reoperation for recurrence of glioblastoma justified?Oncol Rep20007489990410854567
   PubMed Web of Science ®Google Scholar
• BarkerFG2ndChangSMGutinPHSurvival and functional status after resection of recurrent glioblastoma multiformeNeurosurgery19984247097209574634
   PubMed Web of Science ®Google Scholar
• WellerMCloughesyTPerryJRWickWStandards of care for treatment of recurrent glioblastoma: are we there yet?Neuro Oncol201315142723136223
   PubMed Web of Science ®Google Scholar
• FriedmanHSPradosMDWenPYBevacizumab alone and in combination with irinotecan in recurrent glioblastomaJ Clin Oncol200927284733474019720927
   PubMed Web of Science ®Google Scholar
• KreislTNKimLMooreKPhase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastomaJ Clin Oncol200927574074519114704
   PubMed Web of Science ®Google Scholar
• TabatabaiGStuppRvan den BentMJMolecular diagnostics of gliomas: the clinical perspectiveActa Neuropathol2010120558559220862485
   PubMed Web of Science ®Google Scholar
• GorliaTvan den BentMJHegiMENomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3Lancet Oncol200891293818082451
   PubMed Web of Science ®Google Scholar
• MirimanoffROGorliaTMasonWRadiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trialJ Clin Oncol200624162563256916735709
   PubMed Web of Science ®Google Scholar
• BucknerJCFactors influencing survival in high-grade gliomasSemin Oncol2003306 Suppl 19101414765378
   PubMed Web of Science ®Google Scholar
• IchimuraKPearsonDMKocialkowskiSIDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomasNeuro Oncol200911434134719435942
   PubMed Web of Science ®Google Scholar
• YanHParsonsDWJinGIDH1 and IDH2 mutations in gliomasN Engl J Med2009360876577319228619
   PubMed Web of Science ®Google Scholar
• DangLWhiteDWGrossSCancer-associated IDH1 mutations produce 2-hydroxyglutarateNature2010465730096620559394
   PubMed Web of Science ®Google Scholar
• ParsonsDWJonesSZhangXAn integrated genomic analysis of human glioblastoma multiformeScience200832158971807181218772396
   PubMed Web of Science ®Google Scholar
• WickWHartmannCEngelCNOA-04 randomized phase III trial of sequential chemoradiotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomideJ Clin Oncol200927355874588019901110
   PubMed Web of Science ®Google Scholar
• HartmannCHentschelBWickWPatients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomasActa Neuropathol2010120670771821088844
   PubMed Web of Science ®Google Scholar
• ThonNEigenbrodSKrethSIDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survivalCancer2012118245246021717448
   PubMed Web of Science ®Google Scholar
• OhgakiHKleihuesPGenetic pathways to primary and secondary glioblastomaAm J Pathol200717051445145317456751
   PubMed Web of Science ®Google Scholar
• StanderMPeraudALerochBKrethFWPrognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysisCancer200410151028103515329912
   PubMed Web of Science ®Google Scholar
• AgarwalMLAgarwalATaylorWRStarkGRp53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblastsProc Natl Acad Sci U S A19959218849384977667317
   PubMed Web of Science ®Google Scholar
• CairncrossGWangMShawEPhase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402J Clin Oncol201331333734323071247
   PubMed Web of Science ®Google Scholar
• van den BentMJBrandesAATaphoornMJAdjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951J Clin Oncol201331334435023071237
   PubMed Web of Science ®Google Scholar
• HegiMEJanzerRCLambivWLPresence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trialActa Neuropathol2012123684185222249618
   PubMed Web of Science ®Google Scholar
• Boots-SprengerSHSijbenARijntjesJSignificance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with cautionMod Pathol201326792292923429602
   PubMed Web of Science ®Google Scholar
• WellerMStuppRHegiMEPersonalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practiceNeuro Oncol201214Suppl 4iv100iv10823095825
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NetworkComprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature200845572161061106818772890
   PubMed Web of Science ®Google Scholar
• WellerMFelsbergJHartmannCMolecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma NetworkJ Clin Oncol200927345743575019805672
   PubMed Web of Science ®Google Scholar
• SuzukiMMBirdADNA methylation landscapes: provocative insights from epigenomicsNat Rev Genet20089646547618463664
   PubMed Web of Science ®Google Scholar
• IrizarryRALadd-AcostaCWenBThe human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shoresNat Genet200941217818619151715
   PubMed Web of Science ®Google Scholar
• ChenZXRiggsADDNA methylation and demethylation in mammalsJ Biol Chem201128621183471835321454628
   PubMed Web of Science ®Google Scholar
• HellmanAChessAGene body-specific methylation on the active X chromosomeScience200731558151141114317322062
   PubMed Web of Science ®Google Scholar
• EstellerMCancer epigenomics: DNA methylomes and histone-modification mapsNat Rev Genet20078428629817339880
   PubMed Web of Science ®Google Scholar
• RobertsonKDDNA methylation and human diseaseNat Rev Genet20056859761016136652
   PubMed Web of Science ®Google Scholar
• EstellerMCornPGBaylinSBHermanJGA gene hypermethylation profile of human cancerCancer Res20016183225322911309270
   PubMed Web of Science ®Google Scholar
• CadieuxBChingTTVandenbergSRCostelloJFGenome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferationCancer Res200666178469847616951158
   PubMed Web of Science ®Google Scholar
• MartinezRMartin-SuberoJIRohdeVA microarray-based DNA methylation study of glioblastoma multiformeEpigenetics20094425526419550145
   PubMed Web of Science ®Google Scholar
• WuXRauchTAZhongXCpG island hypermethylation in human astrocytomasCancer Res20107072718272720233874
   PubMed Web of Science ®Google Scholar
• AgnihotriSWolfAMunozDMA GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomasJ Exp Med2011208468970221464220
   PubMed Web of Science ®Google Scholar
• TepelMRoerigPWolterMFrequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastomaInt J Cancer200812392080208618709645
   PubMed Web of Science ®Google Scholar
• NakamuraMWatanabeTYonekawaYKleihuesPOhgakiHPromoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C –>A:T mutations of the TP53 tumor suppressor geneCarcinogenesis200122101715171911577014
   PubMed Web of Science ®Google Scholar
• NakamuraMWatanabeTKlangbyUp14ARF deletion and methylation in genetic pathways to glioblastomasBrain Pathol200111215916811303791
   PubMed Web of Science ®Google Scholar
• StoneARBoboWBratDJDeviNSVan MeirEGVertinoPMAberrant methylation and down-regulation of TMS1/ASC in human glioblastomaAm J Pathol200416541151116115466382
   PubMed Web of Science ®Google Scholar
• KoslaKPluciennikEKurzykAMolecular analysis of WWOX expression correlation with proliferation and apoptosis in glioblastoma multiformeJ Neurooncol2011101220721320535528
   PubMed Web of Science ®Google Scholar
• WahaAGüntnerSHuangTHEpigenetic silencing of the protocadherin family member PCDH-gamma-A11 in astrocytomasNeoplasia20057319319915799819
   PubMed Web of Science ®Google Scholar
• LindemannCHackmannODelicSSchmidtNReifenbergerGRiemenschneiderMJSOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activationActa Neuropathol2011122224125121590492
   PubMed Web of Science ®Google Scholar
• AlonsoMMDiez-ValleRManterolaLGenetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomasPLoS One2011611e2674022069467
   PubMed Web of Science ®Google Scholar
• UhlmannKRohdeKZellerCDistinct methylation profiles of glioma subtypesInt J Cancer20031061525912794756
   PubMed Web of Science ®Google Scholar
• VerhaakRGHoadleyKAPurdomEIntegrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell20101719811020129251
   PubMed Web of Science ®Google Scholar
• NoushmehrHWeisenbergerDJDiefesKIdentification of a CpG island methylator phenotype that defines a distinct subgroup of gliomaCancer Cell201017551052220399149
   PubMed Web of Science ®Google Scholar
• FigueroaMEAbdel-WahabOLuCLeukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiationCancer Cell201018655356721130701
   PubMed Web of Science ®Google Scholar
• WilliamsKChristensenJPedersenMTTET1 and hydroxymethylcytosine in transcription and DNA methylation fidelityNature2011473734734334821490601
   PubMed Web of Science ®Google Scholar
• GuoJUSuYZhongCMingGLSongHHydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brainCell2011145342343421496894
   PubMed Web of Science ®Google Scholar
• LuCWardPSKapoorGSIDH mutation impairs histone demethylation and results in a block to cell differentiationNature2012483739047447822343901
   PubMed Web of Science ®Google Scholar
• XuWYangHLiuYOncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenasesCancer Cell2011191173021251613
   PubMed Web of Science ®Google Scholar
• JinSGJiangYQiuR5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutationsCancer Res201171247360736522052461
   PubMed Web of Science ®Google Scholar
• KrausTFGlobischDWagnerMLow values of 5-hydroxymethylcytosine (5hmC), the “sixth base,” are associated with anaplasia in human brain tumorsInt J Cancer201213171577159022234893
   PubMed Web of Science ®Google Scholar
• PeggAERepair of O(6)-alkylguanine by alkyltransferasesMutat Res20004622–38310010767620
   PubMed Web of Science ®Google Scholar
• GersonSLMGMT: its role in cancer aetiology and cancer therapeuticsNat Rev Cancer20044429630715057289
   PubMed Web of Science ®Google Scholar
• PreusserMCharles JanzerRFelsbergJAnti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarkerBrain Pathol200818452053218400046
   PubMed Web of Science ®Google Scholar
• HegiMEDiserensACGorliaTMGMT gene silencing and benefit from temozolomide in glioblastomaN Engl J Med200535210997100315758010
   PubMed Web of Science ®Google Scholar
• EllingsonBMCloughesyTFPopeWBAnatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomasNeuroimage201259290891622001163
   PubMed Web of Science ®Google Scholar
• LevnerIDrabyczSRoldanGde RoblesPCairncrossJGMitchellRPredicting MGMT methylation status of glioblastomas from MRI textureMed Image Comput Comput Assist Interv200912Pt 252253020426152
   PubMedGoogle Scholar
• RomanoACalabriaLFTavantiFApparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation statusEur Radiol201323251352022875158
   PubMed Web of Science ®Google Scholar
• ParkCKKimJYimSYUsefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patientsNeuro Oncol201113219520221075779
   PubMed Web of Science ®Google Scholar
• BrandesAAFranceschiETosoniAMGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant chemoradiotherapy in newly diagnosed glioblastoma patientsJ Clin Oncol200826132192219718445844
   PubMed Web of Science ®Google Scholar
• NiyaziMSchnellOSuchorskaBFET-PET assessed recurrence pattern after radio-chemotherapy in newly diagnosed patients with glioblastoma is influenced by MGMT methylation statusRadiother Oncol20121041788222673727
   PubMed Web of Science ®Google Scholar
• DrabyczSRoldánGde RoblesPAn analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imagingNeuroimage20104921398140519796694
   PubMed Web of Science ®Google Scholar
• AhluwaliaMSAmerican Society of Clinical Oncology. 2011 CNS tumors updateExpert Rev Anticancer Ther201111101495149721999122
   PubMed Web of Science ®Google Scholar
• ReifenbergerGHentschelBFelsbergJPredictive impact of MGMT promoter methylation in glioblastoma of the elderlyInt J Cancer201213161342135022139906
   PubMed Web of Science ®Google Scholar
• GilbertMRWangMAldapeKRTOG 0525: a randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM)Neuro Oncol2011135121123368
   PubMed Web of Science ®Google Scholar
• BaurMPreusserMPiribauerMFrequent MGMT (0(6)-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experienceRadiol Oncol201044211312022933901
   PubMed Web of Science ®Google Scholar
• FelsbergJThonNEigenbrodSPromoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomasInt J Cancer2011129365967021425258
   PubMed Web of Science ®Google Scholar
• van den BentMJDubbinkHJSansonMMGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951J Clin Oncol200927355881588619901104
   PubMed Web of Science ®Google Scholar
• BadyPSciuscioDDiserensACMGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-statusActa Neuropathol2012124454756022810491
   PubMed Web of Science ®Google Scholar
• Della PuppaAPersanoLMasiGMGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients?J Neurooncol20121061334121725802
   PubMed Web of Science ®Google Scholar
• HermanJGGraffJRMyohanenSNelkinBDBaylinSBMethylation-specific PCR: a novel PCR assay for methylation status of CpG islandsProc Natl Acad Sci U S A19969318982198268790415
   PubMed Web of Science ®Google Scholar
• ChristiansAHartmannCBennerAMeyerJPrognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastomaPLoS One201273e3344922428052
   PubMed Web of Science ®Google Scholar
• McDonaldKLAwGKleihuesPRole of biomarkers in the clinical management of glioblastomas: what are the barriers and how can we overcome them?Front Neurol2012318823346075
   PubMed Web of Science ®Google Scholar
• EstellerMGarcia-FoncillasJAndionEInactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agentsN Engl J Med2000343191350135411070098
   PubMed Web of Science ®Google Scholar
• MollemannMWolterMFelsbergJCollinsVPReifenbergerGFrequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumorsInt J Cancer2005113337938515455350
   PubMed Web of Science ®Google Scholar
• Grasbon-FrodlEMKrethFWRuiterMIntratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomasInt J Cancer2007121112458246417691113
   PubMed Web of Science ®Google Scholar
• MalleyDSHamoudiRAKocialkowskiSPearsonDMCollinsVPIchimuraKA distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenograftsActa Neuropathol2011121565166121287394
   PubMed Web of Science ®Google Scholar
• van VlodropIJNiessenHEDerksSAnalysis of promoter CpG island hypermethylation in cancer: location, location, location!Clin Cancer Res201117134225423121558408
   PubMed Web of Science ®Google Scholar
• KrethSThonNEigenbrodSO-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylationPLoS One201162e1715621365007
   PubMed Web of Science ®Google Scholar
• LalezariSChouAPTranACombined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcomeNeuro Oncol201315337038123328811
   PubMed Web of Science ®Google Scholar
• KrethSLimbeckEHinskeLCIn human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencingActa Neuropathol2013125567168123340988
   PubMed Web of Science ®Google Scholar
• AgnihotriSGajadharASTernamianCAlkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patientsJ Clin Invest2012122125326622156195
   PubMed Web of Science ®Google Scholar
• WellerMPlattenMRothPWickWGeriatric neuro-oncology: from mythology to biologyCurr Opin Neurol201124659960421968549
   PubMed Web of Science ®Google Scholar
• LaperriereNWellerMStuppROptimal management of elderly patients with glioblastomaCancer Treat Rev201339435035722722053
   PubMed Web of Science ®Google Scholar
• MalmströmAGrønbergBHMarosiCTemozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trialLancet Oncol201213991692622877848
   PubMed Web of Science ®Google Scholar
• GrossmanSAYeXChamberlainMTalampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trialJ Clin Oncol200927254155416119636006
   PubMed Web of Science ®Google Scholar
• PeereboomDMShepardDRAhluwaliaMSPhase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiformeJ Neurooncol2010981939919960228
   PubMed Web of Science ®Google Scholar
• WeilerMHartmannCWiewrodtDChemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomideInt J Radiat Oncol Biol Phys201077367067619836157
   PubMed Web of Science ®Google Scholar
• LaiATranANghiemphuPLPhase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiformeJ Clin Oncol201129214214821135282
   PubMed Web of Science ®Google Scholar
• StuppRHegiMENeynsBPhase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastomaJ Clin Oncol201028162712271820439646
   PubMed Web of Science ®Google Scholar
• ColmanHZhangLSulmanEPA multigene predictor of outcome in glioblastomaNeuro Oncol2010121495720150367
   PubMed Web of Science ®Google Scholar